KCP-506
A novel non-opioid for the treatment of chronic pain

Significant unmet medical needs persist for patients suffering from chronic pain. Current therapies have limited efficacy and unfavorable side effects while opioid-based therapies lead to tolerance and addiction. More than 191 million opioid prescriptions were dispensed in 2017 and ~130 Americans die from an opioid overdose every day.1   The opioid epidemic has become a modern health crisis.

Kineta is developing KCP-506, a novel non-opioid therapy for the treatment of chronic neuropathic pain. This highly potent α9α10 nAChR antagonist has demonstrated robust analgesic, anti-inflammatory and neuroprotective effects across multiple animal chronic pain models. It offers the potential of a disease modifying therapy that may slow or halt the progression of chronic pain.

The α9α10 nAChR drug target is not expressed in the central nervous system and may lead to a safer therapy with no centrally mediated toxicities. Unlike other chronic pain therapies, Kineta’s α9α10 nAChR antagonists are non-addictive and non-tolerizing in preclinical studies.

Kineta’s α9α10 nAChR antagonists may be an effective treatment for many types of chronic pain including radiculopathy, chemotherapy-induced peripheral neuropathy (CIPN) and diabetic neuropathy. The global neuropathic pain market was $ 5.5 billion in 2017 and is expected to reach to $ 8.1 billion by 2023. 2


References:
1. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2017
2. Market Research Future: Neuropathic Pain Market Research Report Forecast to 2023 Dec, 2018